PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
Phase 3
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 839
- Registration Number
- NCT00254904
- Locations
- 🇬🇧
Pfizer Investigational Site, Wolverhampton, United Kingdom
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
Phase 3
Completed
- Conditions
- Chronic Bronchitis
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 398
- Registration Number
- NCT00254566
- Locations
- 🇹🇭
Pfizer Investigational Site, Khon Kaen, Thailand
Study of SU011248 in Patients With Advanced Kidney Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: SU011248 capsule
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2010-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51
- Registration Number
- NCT00254540
- Locations
- 🇯🇵
Pfizer Investigational Site, Yamagata, Japan
A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects
Phase 4
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2009-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00251030
- Locations
- 🇺🇸
Pfizer Investigational Site, Kalamazoo, Michigan, United States
Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects
Phase 1
Terminated
- Conditions
- Elderly, Frail
- Interventions
- Procedure: Vitamin D Placebo + ExerciseProcedure: Vitamin D Placebo + Sham ExerciseDrug: Vitamin D + Sham ExerciseDrug: Vitamin D + Exercise
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00249704
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Phase 2
Completed
- Conditions
- Liver NeoplasmsUnresectable Hepatocellular Carcinoma
- Interventions
- Drug: Sunitinib (SU011248)
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00247676
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
US Inhaled Insulin Dose Titration Study
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00246623
- Locations
- 🇺🇸
Pfizer Investigational Site, Bennington, Vermont, United States
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Drug: SU011248Drug: Chemotherapy
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 217
- Registration Number
- NCT00246571
- Locations
- 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Phase 4
Completed
- Conditions
- HIV Infection
- Interventions
- Drug: Nelfinavir mesylate, 625 mg
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00246610
- Locations
- 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1372
- Registration Number
- NCT00244426
- Locations
- 🇮🇹
Pfizer Investigational Site, Viterbo, Italy
© Copyright 2025. All Rights Reserved by MedPath